DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jee Eun | - |
dc.contributor.author | Kim, Jung Eun | - |
dc.contributor.author | Lee, Mi Hwa | - |
dc.contributor.author | Song, Hye Kyoung | - |
dc.contributor.author | Ghee, Jung Yeon | - |
dc.contributor.author | Kang, Young Sun | - |
dc.contributor.author | Min, Hye Sook | - |
dc.contributor.author | Kim, Hyun Wook | - |
dc.contributor.author | Cha, Jin Joo | - |
dc.contributor.author | Han, Jee Young | - |
dc.contributor.author | Han, Sang Youb | - |
dc.contributor.author | Cha, Dae Ryong | - |
dc.date.accessioned | 2021-09-04T00:14:53Z | - |
dc.date.available | 2021-09-04T00:14:53Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-05 | - |
dc.identifier.issn | 0023-6837 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88815 | - |
dc.description.abstract | Although dipeptidyl peptidase IV (DPPIV) inhibitors are known to have renoprotective effects, the mechanism underlying these effects has remained elusive. Here we investigated the effects of DA-1229, a novel DPPIV inhibitor, in two animal models of renal injury including db/db mice and the adriamycin nephropathy rodent model of chronic renal disease characterized by podocyte injury. For both models, DA-1229 was administered at 300 mg/kg/day. DPPIV activity in the kidney was significantly higher in diabetic mice compared with their nondiabetic controls. Although DA-1229 did not affect glycemic control or insulin resistance, DA-1229 did improve lipid profiles, albuminuria and renal fibrosis. Moreover, DA-1229 treatment resulted in decreased urinary excretion of nephrin, decreased circulating and kidney DPPIV activity, and decreased macrophage infiltration in the kidney. In adriamycin-treated mice, DPPIV activity in the kidney and urinary nephrin loss were both increased, whereas glucagon-like peptide-1 concentrations were unchanged. Moreover, DA-1229 treatment significantly improved proteinuria, renal fibrosis and inflammation associated with decreased urinary nephrin loss, and kidney DPP4 activity. In cultured podocytes, DA-1229 restored the high glucose/angiotensin II-induced increase of DPPIV activity and preserved the nephrin levels in podocytes. These findings suggest that activation of DPPIV in the kidney has a role in the progression of renal disease, and that DA-1229 may exert its renoprotective effects by preventing podocyte injury. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject | GLUCAGON-LIKE PEPTIDE-1 | - |
dc.subject | IMPROVES INSULIN-RESISTANCE | - |
dc.subject | MOLECULAR-MECHANISMS | - |
dc.subject | DPP-4 INHIBITION | - |
dc.subject | PROTEINURIA | - |
dc.subject | KIDNEY | - |
dc.subject | MICE | - |
dc.subject | NEPHROPATHY | - |
dc.subject | SITAGLIPTIN | - |
dc.subject | EXPRESSION | - |
dc.title | DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Young Sun | - |
dc.contributor.affiliatedAuthor | Cha, Jin Joo | - |
dc.contributor.affiliatedAuthor | Cha, Dae Ryong | - |
dc.identifier.doi | 10.1038/labinvest.2016.34 | - |
dc.identifier.scopusid | 2-s2.0-84964745293 | - |
dc.identifier.wosid | 000374918400006 | - |
dc.identifier.bibliographicCitation | LABORATORY INVESTIGATION, v.96, no.5, pp.547 - 560 | - |
dc.relation.isPartOf | LABORATORY INVESTIGATION | - |
dc.citation.title | LABORATORY INVESTIGATION | - |
dc.citation.volume | 96 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 547 | - |
dc.citation.endPage | 560 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pathology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pathology | - |
dc.subject.keywordPlus | GLUCAGON-LIKE PEPTIDE-1 | - |
dc.subject.keywordPlus | IMPROVES INSULIN-RESISTANCE | - |
dc.subject.keywordPlus | MOLECULAR-MECHANISMS | - |
dc.subject.keywordPlus | DPP-4 INHIBITION | - |
dc.subject.keywordPlus | PROTEINURIA | - |
dc.subject.keywordPlus | KIDNEY | - |
dc.subject.keywordPlus | MICE | - |
dc.subject.keywordPlus | NEPHROPATHY | - |
dc.subject.keywordPlus | SITAGLIPTIN | - |
dc.subject.keywordPlus | EXPRESSION | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.